Details

Autor(en) / Beteiligte

• López‐Gálvez, Raquel
• Rivera‐Caravaca, José Miguel
• Anguita Sánchez, Manuel
• Sanmartín Fernández, Marcelo
• Rafols, Carles
• Pérez‐Cabeza, Alejandro Isidoro
• Barón Esquivias, Gonzalo
• Lekuona Goya, Iñaki
• Vázquez Rodríguez, José Manuel
• Cosín Sales, Juan
• Arribas Ynsaurriaga, Fernando
• Barrios, Vivencio
• Freixa‐Pamias, Román
• Marín, Francisco

Titel

Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

Ist Teil von

• European journal of clinical investigation, 2022-09, Vol.52 (9), p.e13788-n/a

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2022

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Background In atrial fibrillation (AF) patients on vitamin K antagonists, a progressive deterioration of renal function is common but there is limited evidence with long‐term use of rivaroxaban. Herein, we investigated the change in renal function in AF patients after 2 years of rivaroxaban treatment. Methods The EMIR registry is an observational and multicentre study including AF patients treated with rivaroxaban for at least 6 months prior to inclusion. Changes in analytical parameters were recorded during 2 years of follow‐up. Renal function was estimated using the Cockroft‐Gault equation. Results 1433 patients (638, 44.5% women, mean age of 74.2 ± 9.7 years) were included. Creatinine clearance (CrCl) was available at baseline and at 2 years in 1085 patients. At inclusion, 33.2% of patients had impaired renal function (CrCl <60 ml/min). At 2 years, we were not able to find changes in the proportion of patients with impaired renal function, which increased to 34.6% (p = 0.290). However, the baseline mean CrCl was 76.0 ± 30.5 ml/min and slightly improved at 2 years (77.0 ± 31.8 ml/min; p = 0.014). Overall, the proportion of patients with CrCl <60 ml/min at baseline that had CrCl ≥60 ml/min at 2 years was significantly higher compared to that of patients with CrCl ≥60 ml/min at baseline and CrCl <60 ml/min after (22.2% vs. 13.1%; p < 0.001) Conclusions In AF patients on long‐term rivaroxaban therapy, a decrease in renal function was not observed. We even observed a slight improvement in the patients with renal impairment. These results reinforce the idea that rivaroxaban may be a safe option even in patients with renal impairment.